Janux Therapeutics, Inc. · NASDAQ:JANX
Janux Therapeutics — Corporate Update (July 2023)
19 slides from Janux Therapeutics's corporate update, Jul 17, 2023
Slide 1: Program Updates July 2023
Program Updates July 2023 Exhibit 99.2
Slide 2: Forward-looking statements and disclaimers
Forward-looking statements and disclaimers This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking sta
Slide 3: Multiple programs in Janux drug development pipeline
Multiple programs in Janux drug development pipeline Clinically validated targets Stage of Development Program Target(s) Initial Indication(s) Discovery IND-Enabling Phase 1 Phase 2 Phase 3 TRACTr Programs PSMA-TRACTr JANX007 PSMAxCD3 mCRPC EGFR-TRACTr JANX008 EGFRxCD3 CRC, HNC, NSCLC, RCC TROP2-TRA
Slide 4: T-cell engagers represent an effective approach to trigger anti-tumor immune responses
T-cell engagers represent an effective approach to trigger anti-tumor immune responses Solid tumor treatments have been hindered by safety and PK challenges Ongoing clinical challenges Cytokine-release syndrome (CRS) toxicity Multiple third-party clinical program terminations On-target healthy tissu
Slide 5: TRACTr platform update overview
TRACTr platform update overview Interim clinical data provides first insights into TRACTr performance in humans* PSMA-TRACTr clinical data consistent with TRACTr mechanism-of-action Meaningful PSA drops coupled with manageable safety and CRS profile PK exposure demonstrated TRACTr activation with la
Slide 6: PSMA-TRACTr Program
PSMA-TRACTr Program ) Janux
Slide 7: PSMA-TRACTr dose escalation and expansions in mCRPC patients
PSMA-TRACTr dose escalation and expansions in mCRPC patients Phase 1a dose escalation (3+3) Cohort 1 FPI Oct 2022 Cohort 2 Additional Cohorts Cohort 3 Efficacy: PSA reductions Safety: CRS & healthy tissue PK: TRACTr & active TCE Evidence of mask cleavage Immunogenicity 1 cycle: 21 days, every week x
Slide 8: Janux TRACTr platform design principles
Janux Tumor Activated T-Cell Engager (TRACTr) platform design principles Each program is designed as a potent T-cell engager with reduced toxicity Healthy Tissue Healthy Tissue Improved Safety Masks block binding to targets in healthy tissues Inhibits immune response against healthy tissues Reduces
Slide 9: Interim clinical PK data consistent with TRACTr design principles
Interim clinical PK data has been consistent with TRACTr design principles TRACTr cleavage without TCE accumulation observed JANX007 interim PK data in humans showed consistency with tumor cleavage dependent activity Human Exposure of TRACTr Components TRACTr plasma levels below preclinical activity
Slide 10: PSMA-TRACTr designed to address dosing, CRS and safety limitations of early generation TCEs
PSMA-TRACTr designed to address dosing, CRS and safety limitations of early generation TCEs PSMA is a validated oncology target with large market opportunity Clinical efficacy has been demonstrated with early generation PSMA-TCEs Clinical validation for PSMA-TCE treatment Reported efficacy in multip
Slide 11: TCE mediated immune responses in PSMA(+) tissues trigger cytokine release
TCE mediated immune responses in PSMA(+) healthy & tumor tissues trigger cytokine release that leads to CRS TRACTrs are designed to prevent T-cell activation and cytokine release in healthy tissues Adapted from Arvedson, 2022 CRS Tumor Proteases
Slide 12: JANX007 interim clinical data
JANX007 interim clinical data Best Overall % Change in PSA Values From Baseline* PSA reduction combined with manageable CRS profile consistent with TRACTr MOA and supports continued clinical development Grade 1 - fever Grade 2 - fever; hypotension (no vasopressors required); hypoxia (low flow nasal
Slide 13: Competitor clinical PSA reduction and CRS rate comparisons with JANX007
P50 P50 P50 P50 P30 P30 G3 G3 G2 G2 G2 G2 G1 G1 G1 G1/2 Competitor clinical PSA reduction and CRS rate comparisons with JANX007 Differentiated PSA and CRS profile compared to the other clinical programs JANX007 exhibited encouraging combination of PSA drops with manageable CRS Competitive PSA drops
Slide 14: Assessing tissue contributions to CRS in clinical programs
Assessing tissue contributions to CRS in clinical programs Patients exhibiting CRS without a PSA drop may indicate PSMA(+) healthy tissue activity JANX007 design showed consistency with tumor specific activity and reduced PSMA(+) healthy tissue activity mCRPC Patient PSMA(+) Tissue TCE Activity Site
Slide 15: Treatment related adverse events
Treatment related adverse events Well-tolerated with no dose limiting toxicities to date CRS and related events were low-grade, transient and limited to cycle-1, low frequency of other AEs 28 June 2023 data cutoff; *CRS-related Preferred Term All Subjects (n=8) Grade 1 Grade 2 Grade ≥3 All Grades Cy
Slide 16: On-target, off-tumor toxicity comparisons for PSMA-TCE clinical programs
On-target, off-tumor toxicity comparisons for PSMA-TCE clinical programs PSMA expressed in liver, GI tract, salivary glands and kidney PSMA(+) Tissue Adverse Event JNJ-8081 HPN424 AMG160 JANX007 G1-2 / ³ G3 G1-2 / ³ G3 G1-2 / ³ G3 G1-2 / ³ G3 Liver* Transaminitis 0% / 8% 0% / 21% 0% / 53% NONE Small
Slide 17: Step doses intended to lower the risk of CRS to facilitate higher target doses
Step doses intended to lower the risk of CRS to facilitate higher target doses Higher target doses may improve efficacy Janux clinical development has shifted to dose optimization with the aim to maximize efficacy with manageable safety CRS Grade Over First Infusions Dose Optimization Step size Dose
Slide 18: Update summary
Update summary TRACTr platform clinical proof-of-principle supported by interim data First evidence of tumor-activated T cell engagement for the TRACTr platform in patients with prostate cancer Both PSMA-TRACTr and EGFR-TRACTr have been generally well tolerated at dose levels above the projected MTD
Slide 19: David Campbell, Ph.D. President and CEO
David Campbell, Ph.D. President and CEO 10955 Vista Sorrento Parkway San Diego, CA 92130 dcampbell@januxrx.com